U.S. markets open in 1 hour 4 minutes
  • S&P Futures

    3,839.00
    +13.50 (+0.35%)
     
  • Dow Futures

    31,065.00
    +132.00 (+0.43%)
     
  • Nasdaq Futures

    11,708.50
    +34.25 (+0.29%)
     
  • Russell 2000 Futures

    1,746.00
    +7.70 (+0.44%)
     
  • Crude Oil

    113.33
    +1.57 (+1.40%)
     
  • Gold

    1,828.30
    +7.10 (+0.39%)
     
  • Silver

    20.95
    +0.14 (+0.69%)
     
  • EUR/USD

    1.0514
    -0.0011 (-0.11%)
     
  • 10-Yr Bond

    3.2060
    0.0000 (0.00%)
     
  • Vix

    28.54
    +1.59 (+5.90%)
     
  • GBP/USD

    1.2153
    -0.0031 (-0.26%)
     
  • USD/JPY

    136.3900
    +0.2620 (+0.19%)
     
  • BTC-USD

    20,090.09
    -961.08 (-4.57%)
     
  • CMC Crypto 200

    434.44
    -15.62 (-3.47%)
     
  • FTSE 100

    7,332.13
    +8.72 (+0.12%)
     
  • Nikkei 225

    26,804.60
    -244.87 (-0.91%)
     

Is a Surprise Coming for Mersana Therapeutics (MRSN) This Earnings Season?

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Investors are always looking for stocks that are poised to beat at earnings season and Mersana Therapeutics, Inc. MRSN may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.

That is because Mersana Therapeutics is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pretty good indicator of some favorable trends underneath the surface for MRSN in this report.

In fact, the Most Accurate Estimate for the current quarter is currently at a loss of 65 cents per share for MRSN, compared to a broader Zacks Consensus Estimate of a loss of 67 cents per share. This suggests that analysts have very recently bumped up their estimates for MRSN, giving the stock a Zacks Earnings ESP of +2.70% heading into earnings season.

Mersana Therapeutics, Inc. Price and EPS Surprise

Mersana Therapeutics, Inc. Price and EPS Surprise
Mersana Therapeutics, Inc. Price and EPS Surprise

Mersana Therapeutics, Inc. price-eps-surprise | Mersana Therapeutics, Inc. Quote

Why is this Important?

A positive reading for the Zacks Earnings ESP has proven to be very powerful in producing both positive surprises, and outperforming the market. Our recent 10-year backtest shows that stocks that have a positive Earnings ESP and a Zacks Rank #3 (Hold) or better show a positive surprise nearly 70% of the time, and have returned over 28% on average in annual returns (see more Top Earnings ESP stocks here).

Given that MRSN has a Zacks Rank #3 and an ESP in positive territory, investors might want to consider this stock ahead of earnings. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Clearly, recent earnings estimate revisions suggest that good things are ahead for Mersana Therapeutics, and that a beat might be in the cards for the upcoming report.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Mersana Therapeutics, Inc. (MRSN) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research